Transarterial Embolization for Refractory Lateral Epicondylitis
Transarterial embolization (TAE) is an emerging, minimally invasive treatment option for chronic lateral epicondylitis (tennis elbow) that has failed conservative management, with current evidence showing 70-90% clinical success rates and significant pain reduction, though it is not yet included in standard treatment guidelines.
Current Guideline Position
The 2022 ACR Appropriateness Criteria for chronic elbow pain 1 do not include transarterial embolization as a recommended treatment modality. The guidelines emphasize that management for epicondylalgia includes:
- First-line conservative measures: rest, activity modification, analgesia, physical therapy, and corticosteroid injections
- Surgery: reserved for severe or refractory cases
This absence from guidelines reflects that TAE remains an investigational procedure without sufficient high-quality evidence to establish it as standard care.
Evidence for Embolization
Clinical Efficacy
The most recent comprehensive review 2 (2026) demonstrates that TAE for lateral epicondylitis shows:
- Clinical success rates of approximately 80-90%
- Significant pain reduction and functional improvement
- Safe profile with no major complications reported
A 2018 prospective study 3 of 7 lateral epicondylitis cases treated with TAE showed:
- 73% overall clinical success rate (11/15 cases across all tendinopathies)
- Mean VAS scores decreased from 6.1 at baseline to 2.5 at 4 months (p < 0.05)
- 90% success rate in patients with "evident" angiographic enhancement versus 60% without evident enhancement
- Technical success rate of 100%
Mechanism and Technique
TAE targets pathological hypervascularization and neo-innervation that drive chronic pain in refractory tendinopathy 2, 4. The procedure:
- Uses superselective catheter-guided approach to radial collateral vessels
- Employs temporary embolic agents, most commonly imipenem/cilastatin sodium 3, 5
- Alternative agents include microspheres or novel gelatin sponge particles (Smartgel MIRIP) 5
Safety Profile
Reported adverse effects are minor and transient 3, 5:
- Temporary post-procedural pain aggravation
- Transient forearm cutaneous erythema (with microspheres)
- Diffuse ecchymosis and swelling (resolving within days)
- No major complications reported across multiple studies
Clinical Algorithm for Patient Selection
When to Consider TAE:
Confirmed diagnosis of lateral epicondylitis via clinical examination and imaging (ultrasound or MRI showing tendinosis, partial tearing, or associated pathology)
Failed conservative management for at least 3-6 months including:
- Physical therapy with eccentric exercises
- Activity modification
- NSAIDs
- At least one corticosteroid injection trial
Angiographic evidence of pathological neovascularization on pre-procedural assessment
- Patients with "evident enhancement" show significantly better outcomes (4.5 vs 1.8 VAS reduction) 3
Patient factors favoring TAE over surgery:
- Desire to avoid surgical intervention
- Comorbidities increasing surgical risk
- Diabetes mellitus (where steroid injections may be contraindicated) 5
- Need for faster return to function
When NOT to Pursue TAE:
- Acute lateral epicondylitis (< 3 months duration)
- Inadequate trial of conservative therapy
- Absence of neovascularization on imaging
- Patient preference for established surgical options
Current Evidence Limitations
- Most studies are small case series without randomized controlled trials
- Variable follow-up periods and outcome measures
- Lack of standardized technical protocols
- No long-term durability data beyond 1-2 years
- Not yet established as standard of care in major guidelines
- Cost-effectiveness compared to surgery unknown
Practical Recommendation
For patients with chronic lateral epicondylitis refractory to 6 months of comprehensive conservative management, TAE may be offered as a minimally invasive alternative to surgery, particularly in patients with documented neovascularization on imaging and those with contraindications to corticosteroids or surgical intervention 2, 4, 3. However, patients must be counseled that:
- This remains an emerging procedure not yet endorsed by major orthopedic or radiology guidelines
- Evidence quality is moderate with limited long-term data
- Traditional surgical options (open or arthroscopic debridement) remain the established standard for refractory cases
- Best outcomes occur when angiographic hypervascularization is evident pre-procedure 3
The procedure should only be performed at centers with interventional radiology expertise in musculoskeletal embolization and appropriate patient selection protocols 6.